Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients
Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A (2015)
Publication Type: Journal article
Publication year: 2015
Journal
Publisher: Feinstein Institute for Medical Research
Book Volume: 21
Pages Range: 371-80
DOI: 10.2119/molmed.2014.00250
Abstract
Piwi-like 2 (Piwil 2) belongs to the family of Argonaute genes/proteins. The expression of Piwil 2 is associated with stem cells. A role in tumorigenesis and/or tumor progression is proposed for different cancers but not yet for bladder cancer (BCa). We investigated the Piwil 2 expression by immunohistochemistry in a cohort of 202 BCa patients treated by cystectomy and adjuvant chemotherapy. The association between Piwil 2 expression and disease-specific (DSS) or progression-free survival (PFS) was calculated using Kaplan Meier analyses and univariate/multivariate Cox's regression hazard models.In a multivariate Cox's regression, Piwil 2 expression, either in the cytoplasm or the nucleus, was significantly associated with DSS and PFS. A weak cytoplasmic staining pattern was associated with poor DSS and tumor progression (RR=2.7; P=0.004 and RR=2.4; P=0.027). Likewise,, absent nuclear Piwil 2 immunoreactivity was associated with poor DSS and tumor progression (RR=2.3; P=0.023 and RR=2.2; P=0.022). BCa patients whose tumors exhibited a combination of weak cytoplasmic and absent nuclear immunoreactivity had a 6-fold increased risk of tumor-related death (P=0.005) compared to patients with strong expression. Considering only patients with high grade G3 tumors, a 7.8-fold risk of tumor-associated death and a 3.6-fold risk of tumor progression were detected independently of the histologic tumor subtype or the chemotherapy regimen. In summary, a combination of weak cytoplasmic and absent nuclear expression of Piwil 2 is significantly associated with an increased risk of DSS and tumor progression. This implicates that Piwil 2 could be a valuable prognostic marker for high-risk BCa patients.
Authors with CRIS profile
Helge Taubert
Urologische Klinik
Bastian Keck
Medizinische Fakultät
Simone Bertz
Institute of Pathology
Elke Nolte
Professur für Genetik
Bernd Wullich
Lehrstuhl für Urologie
Arndt Hartmann
Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie
Involved external institutions
Germany (DE)How to cite
APA:
Taubert, H., Wach, S., Jung, R., Pugia, M., Keck, B., Bertz, S.,... Hartmann, A. (2015). Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients. Molecular Medicine, 21, 371-80. https://doi.org/10.2119/molmed.2014.00250
MLA:
Taubert, Helge, et al. "Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients." Molecular Medicine 21 (2015): 371-80.
BibTeX: Download